Abstract

The human reduced folate carrier (hRFC) is the dominant transporter mediating the uptake of reduced folate cofactors and antifolate anticancer drugs. Defective antifolate uptake due to inactivating mutations in the hRFC gene is an established mechanism of drug resistance in various tumor cells. However, while antifolate transport is frequently impaired, either no or only a single hRFC allele is inactivated, suggesting that additional mechanism(s) of resistance are operative. Here we studied the relationship between the expression and function of transcription factors and antifolate resistance in transport-defective leukemia cells that poorly express or completely lack RFC mRNA. Stable transfection with a hRFC expression construct resulted in restoration of normal RFC mRNA expression and nearly wild type drug sensitivity in these antifolate-resistant cells. The loss of RFC gene expression prompted us to explore transcription factor binding to the hRFC promoter. The hRFC promoter contains an upstream GC-box and a downstream cAMP-response element (CRE)/AP-1-like element. Electrophoretic mobility shift assays and oligonucleotide competition revealed a substantial loss of nuclear factor binding to CRE and GC-box in these drug-resistant cell lines. Consistently, antibody-mediated supershift analysis showed a marked decrease in the binding of CRE-binding protein 1 (CREB-1) and specificity protein 1 (Sp1) to CRE and GC-box, respectively. Western blot analysis revealed undetectable expression of CREB-1, decreased ATF-1 levels, parental Sp1 levels, and increased levels of the short Sp3 isoforms, recently shown to repress hRFC gene expression. Transient transfections into these antifolate-resistant cells demonstrated a marked loss of GC-box-dependent, and CRE-driven reporter gene activities and introduction of CREB-1 or Sp1 expression constructs resulted in restoration of hRFC mRNA expression. These results establish a novel mechanism of antifolate resistance that is based on altered expression and function of transcription factors resulting in transcriptional silencing of the hRFC promoter.

Highlights

  • Mammalian cells are devoid of reduced folate biosynthesis and meet their folate growth requirement via uptake from exogenous sources (1)

  • The aim of the current study was to identify the molecular basis underlying the loss of reduced folate carrier (RFC) mRNA expression in antifolate-resistant human leukemia cell lines displaying impaired MTX transport

  • These alterations were associated with a prominent decrease in the binding of transcription factors to the inducible (CRE) and constitutive (GC-box) elements in the human RFC (hRFC) promoter, presumably leading to a marked decrease in RFC mRNA expression

Read more

Summary

Introduction

Mammalian cells are devoid of reduced folate biosynthesis and meet their folate growth requirement via uptake from exogenous sources (1). Qualitative (i.e. inactivating mutations) (7–11) and quantitative alterations (i.e. decreased or abolished expression) in human RFC (hRFC) gene expression and/or function are documented mechanisms of MTX resistance in acute lymphoblastic leukemia (ALL) (12, 13) and osteogenic sarcoma patients (14). The human CCRF-CEM leukemia cell lines AG2034R2 and ZD9331R1.5 were isolated, which displayed up to 2300-fold resistance to various antifolates due to abolished drug transport (11). This was a result of a marked decrease (or complete loss) of RFC mRNA expression. The current study constitutes the first demonstration of a novel mechanism of antifolate resistance that is based on alterations in the expression of transcription factors and their binding to the hRFC promoter

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.